CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
出版年份 2013 全文链接
标题
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
作者
关键词
-
出版物
LEUKEMIA
Volume 28, Issue 4, Pages 917-927
出版商
Springer Nature
发表日期
2013-09-26
DOI
10.1038/leu.2013.279
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MicroRNAs activate natural killer cells through Toll-like receptor signaling
- (2013) S. He et al. BLOOD
- NK cell-based immunotherapy for malignant diseases
- (2013) Min Cheng et al. Cellular & Molecular Immunology
- Zoom Zoom: Racing CARs for Multiple Myeloma
- (2013) M. V. Maus et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients
- (2013) Niels WCJ van de Donk et al. EXPERT OPINION ON PHARMACOTHERAPY
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma
- (2012) Jooeun Bae et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
- (2012) Natalia Lapteva et al. CYTOTHERAPY
- Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model
- (2012) B. E. Swift et al. HAEMATOLOGICA
- Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells
- (2012) Roberto Bellucci et al. JOURNAL OF CLINICAL INVESTIGATION
- CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma
- (2012) Don M. Benson et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of natural killer cells in immunity against multiple myeloma
- (2012) James Godfrey et al. LEUKEMIA & LYMPHOMA
- Human NK cell lytic granules and regulation of their exocytosis
- (2012) Konrad Krzewski et al. Frontiers in Immunology
- IFN- Inhibits Gastric Carcinogenesis by Inducing Epithelial Cell Autophagy and T-Cell Apoptosis
- (2011) S. P. Tu et al. CANCER RESEARCH
- The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells
- (2011) E. Narni-Mancinelli et al. INTERNATIONAL IMMUNOLOGY
- T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
- (2011) K Mihara et al. LEUKEMIA
- Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
- (2011) N W C J van de Donk et al. LEUKEMIA
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects
- (2010) J. A. Olson et al. BLOOD
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
- (2010) B. Jena et al. BLOOD
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
- (2009) Y.-T. Tai et al. BLOOD
- CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets
- (2009) J. Yu et al. BLOOD
- Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
- (2009) H. Fujisaki et al. CANCER RESEARCH
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
- (2008) Gema Mateo et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of newly diagnosed myeloma
- (2008) A Palumbo et al. LEUKEMIA
- NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
- (2008) G Maki et al. LEUKEMIA
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
- (2008) A. Kruschinski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now